Web Analytics

Epstein Barr Virus (EBNA) IgG



1x96 Assays
Add to Cart


Please click here for MSDS PDF Datasheet

Product Name: Epstein-Barr Virus (EBNA) recombinant IgG – ELISA

# of Samples: 1 x 96 Assays

Intended Use: The Epstein-Barr Virus (EBV) IgG-ELISA is intended for the qualitative determination of IgG class antibodies against Epstein-Barr virus (EBNA) in human serum or plasma (citrate).

Introduction: Epstein-Barr Virus (EBV) is a member of the herpesvirus family (Gamma subgroup, DNA virus of 120-200 nm) and one of the most common human viruses. The virus occurs worldwide, and most people become infected with EBV sometime during their lives. Transmission of the virus is almost impossible to prevent since many healthy people can carry and spread the virus intermittently for life. Infants become susceptible to EBV as soon as maternal antibody protection disappears. Infection of children usually causes no symptoms. Infection during adolescence or young adulthood causes infectious mononucleosis 35% to 50% of the time.
Infectious mononucleosis is almost never fatal. There are no known associations between active EBV infection and problems during pregnancy, such as miscarriages or birth defects. Although the symptoms of infectious mononucleosis usually resolve in 1 or 2 months, EBV remains dormant or latent in a few cells in the throat and blood for the rest of the person’s life. Periodically, the virus can reactivate and is commonly found in the saliva of infected persons. This reactivation usually occurs without symptoms of illness.
EBV also establishes a lifelong dormant infection in some cells of the body’s immune system. A late event in a very few carriers of this virus is the emergence of Burkitt´s lymphoma and nasopharyngeal carcinoma, but EBV is probably not the sole cause of these malignancies.
The presence of virus resp. infection may be identified by
Serology: “mono spot” test, Detection of antibodies by ELISA
The optimal combination of serologic testing consists of the titration of four markers: IgM and IgG to the viral capsid antigen (VCA), IgM to the early antigen, and antibody to EBV nuclear antigen (EBNA). IgM to VCA appears early in infection and disappears within 4 to 12 weeks. IgG to VCA appears in the acute phase, peaks at 2 to 4 weeks after onset, declines slightly, and then persists for life.
If antibodies to the viral capsid antigen are not detected, the patient is susceptible to EBV infection.

Principles of the assay: The qualitative immunoenzymatic determination of IgG-class antibodies against Epstein-Barr Virus is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique.
Microtiter strip wells are precoated with recombinant Epstein-Barr Virus nulcear antigen EBNA-1 to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgG conjugate is added. This conjugate binds to the captured Epstein-Barr Virus-specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine- (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of Epstein-Barr Virus-specific IgG antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.

Storage and Stability: The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.

Limitations of the Test: A negative result (IgG or IgM) cannot exclude an infection with Epstein Barr Virus. Especially in the early state of infection it is possible that the amount of antibodies is below the detection limit. In case of clinical suspicion to EBV or equivocal test result it is recommended to test another sample after 2-3 weeks.
Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data.
In immunocompromised patients and newborns serological data only have restricted value.

References Bergman M., Gleckman R.A., “Heterophil-negative infectious mononucleosis-like syndrome”. Postgrad.Med., 81 (1): 313-326 (1987)Buchwald D., Komaroff A.L., “Review of laboratory findings for patient with chronic fatique syndrome”. Rev. Inf. Dis., 13 (Suppl. 1): S12-S18 (1991)De Ory F., Antonaya J., Fernandez M.V., Echevarria J.M., “Application of low-avidity immunglobulin G studies to diagnosis of EBV infectious mononucleosis”. J. Clin. Microbiol., 31 (6): 1669-1671, (1993)De-The, G., “Epidemiology of EBV and Associated Diseases in Man”, In: The Herpesviruses, Roizman, B. (ed)., Volume 1, New York: Plenum-Press, 25-103, (1982)Dölken G., Weitzmann U., Boldt C. et al.. “Enzyme linked immunosorbent assay for IgG antibodies of EBV virus associated early antigens and viral capside antigen”.J. Immunol. Meth.., 67: 225-233, (1984)Färber I., Wutzler P., Wohlrabe P. et al., ”Serological diagnosis of infectious mononucleosis using three anti-Epstein-Barr virus recombinant ELISAs“, J. Virol. Meth.; 42: 301-308, (1993)Gorgievski-Hrisoho M., Hinderer W., Nebel-Schickel H. et al., “Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked Immunosorbent assay technology”, J. Clin. Microbiol., 28 (10): 2305-2311, (1990)Halprin J., Scott A.L., Jacoboson L. et al., “Enzyme-linked immunosorbent assay of antibodies to Epstein-Barr virus nuclear and early antigens in patients with infectious mononucleosis and nasopharyngeal carcinoma”, Ann. Int. Med., 104: 331-337, (1986).Heath, C.W., A.L. Brodsky, and A.L. Ptolosky, “Infectious Mononuclelosis in a general population”, Am. J. Epiemiology, 95 (1): 46-52, (1972)Henle W., Henle GE., Horwitz CA., „Epstein-Barr virus specific giagnostic tests in infectious mononucleosis”, Human Pathol., 5 (5): 551-565, (1974)Lamy ME., Favart AM., Cornu A. et al., “Study of Epstein-Barr virus (EBV) antibodies: IgG and IgM anti-VCA, IgG anti EA and Ig anti-EBNA obtained with an original microtiter technique. Serological criterions of primary and recurrents EBV infections and follow-up of infectious mononucleosis. Seroepidemiology of EBV in Belgium based on 5178 sera from patients”. Acta Clin. Belg., 37 (5): 281-298, (1982)Lennette E., „Epstein-Barr Virus“, in Manual of Clinical Microbiology, 4th ed. Washington D.C., Am. Soc. Microbiol. P 728-732, (1985)Luka J., chase PC., Pearson GR., “A sensitive enzyme-linked Immunosorbent assay (ELISA) against the major EBV-associated antigens. I-Correlation between ELISA and immunofluorescence titers using purified antigens”, J. Immunol. Metho., 67: 145-156, (1984)Pearson GP., “Infectious Mononucleosis: the humoral response”, In: Infectious mononucleosis, D. Schlossberg ed., Springer-Verlag, New York, p. 89-99, (1989)Pocheldy C., “Laboratory testing for infectious mononucleosis: cautions to observe in interpreting results”. Prostgrad. Med., 81 (1): 335-342 (1987)Purtilo BT., Hinrichs S., „Detection of Epstein-Barr Virus induced deseases by laboratory techniques“, Incstar Monograph, (1993)

Additional Information

Name Epstein Barr Virus (EBNA) IgG
Related Product Names Epstein-Barr Virus (EBNA) recombinant IgG – ELISA
Molecular Weight 0.5
Datasheets / Downloads GWB-5ED61E Datasheet
Storage The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.
Intended Use Research Use Only